Lornoxicam-d4 - CAS 1216527-48-8

Lornoxicam-d4 is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells, which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells, which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 μM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg. Formulations containing lornoxicam have been used in the management of postoperative pain.

Endogenous Metabolite, COX

Metabolism, Immunology/Inflammation, Neuroscience

1216471

C13H6ClD4N3O4S2

375.85

OC=1C2=C(S(=O)(=O)N(C)C1C(NC3=C(C(=C(C(=N3)[2H])[2H])[2H])[2H])=O)C=C(Cl)S2

-20°C

Ice Packs

Isotope products